Navigation Links
New drug target improves memory in mouse model of Alzheimer's disease
Date:3/7/2012

Researchers at the University of California, San Diego, the Medical University of South Carolina, the University of Cincinnati, and American Life Science Pharmaceuticals of San Diego have validated the protease cathepsin B (CatB) as a target for improving memory deficits and reducing the pathology of Alzheimer's disease (AD) in an animal model representative of most AD patients. The study has been published in the online edition of the Journal of Alzheimer's Disease.

According to investigator Vivian Y. H. Hook, PhD, professor of the UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences and professor of neurosciences, pharmacology and medicine at the UCSD School of Medicine, the study is important because it could lead to new therapeutics that improve the memory deficits of AD.

Abnormal accumulation of brain amyloid-β peptides (Aβ) is thought to cause the memory loss and amyloid plaque pathology of AD. Aβ peptides are "cut" out from a larger protein called the amyloid precursor protein (APP) by an enzymatic "scissor" called β-secretase, and aggregate to form plaques in the brain regions responsible for memory. Inhibiting the β-secretase "scissors" from "cutting" the APP with a drug would reduce brain Aβ levels and thereby improve memory deficits and reduce amyloid plaque pathology. The vast majority of AD patients have wild-type (WT) β-secretase activity and thus the WT β-secretase has been a target of great interest for a long time.

Another protease, BACE1, has long been thought to be the -secretase involved in AD pathology, because deleting that gene from animal models reduces brain A and plaque pathology. However, deleting the BACE1 gene was reported to make memory deficits worse in a transgenic model having WT β-secretase activity.

Hook and colleagues set off to find a WT β-secretase target, which improves memory deficits while reducing amyloid plaque pathology. In the current paper, the researchers show that CatB is such a target because deleting that gene in a transgenic mouse model having WT -secretase activity improves memory deficits and reduces amyloid plaque, which develop in this model, mimicking that found in AD. In contrast, deleting the BACE1 gene in that transgenic model had no effect on memory deficits or pathology.


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. Marker of Ewing sarcoma: Potential new drug target?
2. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
3. New therapeutic target for most common solid cancer in childhood?
4. Fans Spread the Love on Target Facebook Page and Help Donate $1 Million to Five Charities
5. New Multivitamins Target Concern Over China's Quality Problems
6. Targeted delivery of losartan reduces liver inflammation and scarring
7. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
8. TV Ads Target House Members Who Voted for Obamacare
9. Targeting leukemia cells gene addiction presents new strategy for treatment
10. Hot Pepper Itch Remedy Targets Kidney Disease Patients Suffering From Chronic Pruritus
11. Americans for Responsible Health Care Launch Radio Ads Targeting Seven Democrats, Warning The People Are Watching...
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Livionex, Inc., ... results of a double blind clinical study for its dental gel that shows significant ... national brand of toothpaste containing triclosan. The study was conducted at the Beckman Laser ...
(Date:1/17/2017)... ... January 17, 2017 , ... Physicians ... Sandra Lee as keynote speaker for the 34th Annual Miami Breast Cancer Conference®, ... the announcement, PER® president, Phil Talamo, said, “We are delighted to have Sandra ...
(Date:1/17/2017)... ... January 17, 2017 , ... Lynx Technology Partners ... top US security companies for consecutive years, today announced the appointment of four ... independent board nomination process to a close and positions Lynx for even faster ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, FloSports , a global leader ... new agreement as part of a long-term extension of their media partnership. The partnership, ... of some of the sport’s premier events exclusively on FloWrestling.com as well as usage ...
(Date:1/16/2017)... (PRWEB) , ... January 17, 2017 , ... ... Au Bon Pain, an internationally recognized leader in the fast-casual category, announces a ... such as the Good Egg Breakfast Sandwich, Turkey Mash-Up Sandwich, Cranberry Crunch & ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017  Edwards Lifesciences Corporation ... patient-focused innovations for structural heart disease and critical care ... quarter ended December 31, 2016 after the market closes ... conference call at 5:00 p.m. ET that day to ... conference call, dial (877) 407-8037 or (201) 689-8037.  For ...
(Date:1/17/2017)... KANSAS CITY, Mo. , Jan. 17, 2017 ... selected Velos and its flagship technology platform Velos ... initiatives. CHNC is a benchmarking and ... Care Units at leading children,s hospitals across ... a benchmark of care and short-term outcomes for ...
(Date:1/17/2017)... , January 17, 2017 ReportsnReports.com adds ... report provides an overview of the Anaphylaxis,s therapeutic pipeline with ... comparative analysis at various stages, therapeutics assessment by drug target, ... type, along with latest updates, and featured news and press ... ...
Breaking Medicine Technology: